Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 406 participants.
Also called NCT02477865
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 406 participants
- Registry
-
NCT02477865
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02477865. Randomized; triple masking; primary purpose treatment. Start 2014-03-23 (actual); primary completion 2016-05-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- PEX168(100µg)
- Intervention (Drug)
- PEX168(200µg)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct02477865- Content hash
ea96e9189465d0ad2591838a8e01544c9a767f018bab9b0f9e620ab37cc234a3